Shares of ICON Public Limited (NASDAQ:ICLR – Get Rating) have received an average recommendation of “Buy” from the thirteen analysts that are covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $284.40.
Several research firms have recently issued reports on ICLR. Robert W. Baird reaffirmed a “buy” rating and issued a $285.00 price target on shares of ICON Public in a research report on Friday, May 13th. Guggenheim began coverage on shares of ICON Public in a report on Monday, May 23rd. They issued a “buy” rating and a $285.00 target price for the company. StockNews.com assumed coverage on shares of ICON Public in a report on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research upgraded shares of ICON Public from a “sell” rating to a “hold” rating in a report on Tuesday, March 8th. Finally, Deutsche Bank Aktiengesellschaft upgraded ICON Public from a “hold” rating to a “buy” rating and boosted their price target for the stock from $234.00 to $310.00 in a research note on Monday, April 11th.
NASDAQ:ICLR opened at $227.30 on Friday. The firm has a market capitalization of $18.50 billion, a P/E ratio of 91.29, a PEG ratio of 1.10 and a beta of 0.97. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.13 and a quick ratio of 1.13. ICON Public has a one year low of $199.01 and a one year high of $313.00. The company’s 50-day simple moving average is $231.11 and its 200 day simple moving average is $253.26.
ICON Public (NASDAQ:ICLR – Get Rating) last released its earnings results on Wednesday, April 27th. The medical research company reported $2.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.48 by $0.12. ICON Public had a net margin of 2.58% and a return on equity of 11.33%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.88 billion. During the same period last year, the business earned $2.06 earnings per share. On average, equities research analysts expect that ICON Public will post 10.67 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. KB Financial Partners LLC grew its holdings in ICON Public by 23.4% during the first quarter. KB Financial Partners LLC now owns 1,742 shares of the medical research company’s stock valued at $424,000 after purchasing an additional 330 shares during the period. Laurel Wealth Advisors Inc. grew its holdings in ICON Public by 2.0% during the first quarter. Laurel Wealth Advisors Inc. now owns 2,708 shares of the medical research company’s stock valued at $658,000 after purchasing an additional 54 shares during the period. FORA Capital LLC grew its holdings in ICON Public by 276.2% during the first quarter. FORA Capital LLC now owns 4,642 shares of the medical research company’s stock valued at $1,141,000 after purchasing an additional 3,408 shares during the period. Handelsbanken Fonder AB grew its holdings in ICON Public by 57.4% during the first quarter. Handelsbanken Fonder AB now owns 7,130 shares of the medical research company’s stock valued at $1,734,000 after purchasing an additional 2,600 shares during the period. Finally, MAI Capital Management boosted its stake in shares of ICON Public by 1.7% in the first quarter. MAI Capital Management now owns 4,618 shares of the medical research company’s stock worth $1,123,000 after acquiring an additional 78 shares during the period. Institutional investors own 89.41% of the company’s stock.
ICON Public Company Profile (Get Rating)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in ICON Public right now?
Before you consider ICON Public, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and ICON Public wasn’t on the list.
While ICON Public currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
Tags: #ICON #Public #Limited #NASDAQICLR #Average #Rating #quotBuyquot #Analysts #MarketBeat